| Followers | 36 |
| Posts | 11704 |
| Boards Moderated | 0 |
| Alias Born | 02/26/2016 |
Monday, January 07, 2019 3:18:09 PM
I have repeatedly stated that IMHO a discussion of
Short Interest MUST be viewed as "interest" in the Company
and not a static number.
I'll buy the fact that the shorts did not get active in AVXL
until Late Spring 2016 and not Winter that year as as I had
presumed. I use(d) 4M/36M then and 5M/46M as rounded equivalents.
However, the basic discussion of short interest is not about
shares but about influence due to "control" of Float.
If that does not agree with your philosophy then
more power to you in analysis. I still think the shorts
have had much the best of trading AVXL since let's just call
in Spring 2016. They likely have much more room before
forced covering is thrust upon them. As you note the physical
number of shares held short are more than at the point and given
that static number positions were likely widely held above $7
which was after all both the 2015 list price and last seen in 2016.
So frame your contention as you wish. I will take what I consider
a more technical if perhaps Conservative approach. I am ahead,
even with missteps, in AVXL for my life in the stock.
Would have to re enter to participate further and that may be a
possibility. Sorry if that middle of the road approach does not
meet muster with those who see only positive assertions as worthy
of discussion.
Short Interest MUST be viewed as "interest" in the Company
and not a static number.
I'll buy the fact that the shorts did not get active in AVXL
until Late Spring 2016 and not Winter that year as as I had
presumed. I use(d) 4M/36M then and 5M/46M as rounded equivalents.
However, the basic discussion of short interest is not about
shares but about influence due to "control" of Float.
If that does not agree with your philosophy then
more power to you in analysis. I still think the shorts
have had much the best of trading AVXL since let's just call
in Spring 2016. They likely have much more room before
forced covering is thrust upon them. As you note the physical
number of shares held short are more than at the point and given
that static number positions were likely widely held above $7
which was after all both the 2015 list price and last seen in 2016.
So frame your contention as you wish. I will take what I consider
a more technical if perhaps Conservative approach. I am ahead,
even with missteps, in AVXL for my life in the stock.
Would have to re enter to participate further and that may be a
possibility. Sorry if that middle of the road approach does not
meet muster with those who see only positive assertions as worthy
of discussion.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
